D-Index & Metrics Best Publications

Mark C. Gebhardt

Harvard Medical School
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 86 Citations 29,997 288 World Ranking 9099 National Ranking 4830

Overview

What is he best known for?

The fields of study Mark C. Gebhardt is best known for:

Cancer
Bacteria
Surgery

Mark C. Gebhardt focuses mostly in the field of Stress fractures, narrowing it down to matters related to Radiology and, in some cases, Magnetic resonance imaging. He combines Magnetic resonance imaging and Radiology in his research. Surgery is frequently linked to Cadaveric spasm in his study. Mark C. Gebhardt performs integrative study on Lesion and Pathology in his works. His Pathology study frequently draws connections to other fields, such as Soft tissue. His work often combines Soft tissue and Cancer studies. His multidisciplinary approach integrates Cancer and Lesion in his work. Mark C. Gebhardt conducts interdisciplinary study in the fields of Radiation therapy and Sarcoma through his research. He undertakes interdisciplinary study in the fields of Sarcoma and Soft tissue sarcoma through his research.

His most cited work include:

Infection in bone allografts. Incidence, nature, and treatment. (432 citations)
Fractures of allografts. Frequency, treatment, and end-results. (327 citations)
The Results of Transplantation of Intercalary Allografts after Resection of Tumors. A Long-Term Follow-up Study* (255 citations)

What are the main themes of his work throughout his whole career to date

Mark C. Gebhardt performs integrative study on Surgery and Amputation. Mark C. Gebhardt merges Pathology with Immunology in his research. Mark C. Gebhardt integrates many fields, such as Immunology and Pathology, in his works. Mark C. Gebhardt regularly ties together related areas like Chemotherapy in his Internal medicine studies. Chemotherapy is frequently linked to Internal medicine in his study. Mark C. Gebhardt incorporates Biochemistry and Molecular biology in his studies. While working on this project, Mark C. Gebhardt studies both Molecular biology and Biochemistry. His study deals with a combination of Genetics and Cancer research. He connects Cancer research with Genetics in his study.

Mark C. Gebhardt most often published in these fields:

Surgery (53.85%)
Pathology (38.46%)
Internal medicine (34.62%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system.

William F. Enneking;William Dunham;Mark C. Gebhardt;Martin Malawar.
Clinical Orthopaedics and Related Research (1993)

3155 Citations

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

Holcombe E Grier;Mark D Krailo;Nancy J Tarbell;Michael P Link.
The New England Journal of Medicine (2003)

1355 Citations

p53 functions as a cell cycle control protein in osteosarcomas.

L Diller;J Kassel;C E Nelson;M A Gryka.
Molecular and Cellular Biology (1990)

1073 Citations

Biology and Therapeutic Advances for Pediatric Osteosarcoma

Neyssa Marina;Mark Gebhardt;Lisa Teot;Richard Gorlick.
Oncologist (2004)

852 Citations

Long-term results of allograft replacement in the management of bone tumors.

Henry Mankin;Mark Gebhardt;L. Jennings;Dempsey Springfield.
Clinical Orthopaedics and Related Research (1996)

846 Citations

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Paul A. Meyers;Cindy L. Schwartz;Mark D. Krailo;John H. Healey.
Journal of Clinical Oncology (2008)

758 Citations

Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate

Paul A. Meyers;Cindy L. Schwartz;Mark Krailo;Eugenie S. Kleinerman.
Journal of Clinical Oncology (2005)

750 Citations

Infection in bone allografts. Incidence, nature, and treatment.

C F Lord;M C Gebhardt;W W Tomford;H J Mankin.
Journal of Bone and Joint Surgery, American Volume (1988)

645 Citations

Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment.

Daniel Rosenthal;Francis Hornicek;Michael Wolfe;L. Jennings.
Journal of Bone and Joint Surgery, American Volume (1998)

642 Citations

Osteoid osteoma: percutaneous treatment with radiofrequency energy.

Daniel I Rosenthal;Francis J Hornicek;Martin Torriani;Mark C Gebhardt.
Radiology (2003)

578 Citations

If you think any of the details on this page are incorrect, let us know.